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Background: Large multicentre trials are complex and expensive projects. A key factor for their successful planning
and delivery is how well sites meet their targets in recruiting and retaining participants, and in collecting high-
quality, complete data in a timely manner. Collecting and monitoring easily accessible data relevant to performance
of sites has the potential to improve trial management efficiency. The aim of this systematic review was to identify
metrics that have either been proposed or used for monitoring site performance in multicentre trials.
Methods: We searched the Cochrane Library, five biomedical bibliographic databases (CINAHL, EMBASE, Medline,
PsychINFO and SCOPUS) and Google Scholar for studies describing ways of monitoring or measuring individual site
performance in multicentre randomised trials. Records identified were screened for eligibility. For included studies,
data on study content were extracted independently by two reviewers, and disagreements resolved by discussion.
Results: After removing duplicate citations, we identified 3188 records. Of these, 21 were eligible for inclusion and
yielded 117 performance metrics. The median number of metrics reported per paper was 8, range 1–16. Metrics
broadly fell into six categories: site potential; recruitment; retention; data collection; trial conduct and trial safety.
Conclusions: This review identifies a list of metrics to monitor site performance within multicentre randomised
trials. Those that would be easy to collect, and for which monitoring might trigger actions to mitigate problems at
site level, merit further evaluation.
Keywords: Multicentre, Randomised trials, Clinical trials, Performance metrics, Trial management, Site performance,
Operational metrics, Key performance indicatorsBackground
Multicentre randomised trials are complex and expensive
projects. Improving the efficiency and quality of trial con-
duct is important, for patients, funders, researchers, clini-
cians and policy-makers [1]. A key factor in successful
planning and delivery of multicentre trials is how well sites
meet their targets in recruiting and retaining participants,
and in collecting high-quality, complete data in a timely
manner [2]. Collecting and monitoring easily accessible
data relevant to performance of sites has the potential to
improve the efficiency and success of trial management.
Ideally, such performance metrics should provide infor-
mation that quickly identifies potential problems so they* Correspondence: kate.walker@nottingham.ac.uk
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pact and improving the efficiency of trial conduct.
We are not aware of any standardised metrics for moni-
toring site performance in multicentre trials. A recent query
to all UK Clinical Research Collaboration (UKCRC), regis-
tered Clinical Trials Units (CTUs) revealed that many units
routinely collect and report data for each site in a trial; such
as numbers randomised, case report forms (CRFs) returned,
data quality, missing primary outcome data, and serious
breaches. How such data are used to assess and manage
performance varies widely however [3–7]. Agreeing a small
number of metrics for site performance that could be easily
collected, presented and monitored in a standardised way
by a trial manager or trial co-ordinator would be a poten-
tially useful tool to improve efficient trial conduct.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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committees monitor site performance and trial conduct
based primarily on recruitment [8]. Whilst clearly im-
portant, recruitment is not the only performance indica-
tor that matters for a successful trial. Using a range of
additional metrics that include data quality, protocol
compliance and participant retention would give a better
overall measure of the performance of each trial site,
and the trial overall. To be low cost and efficient, the
number of metrics monitored at any one time should be
limited to no more than 8 to 12 [9]. We conducted a sys-
tematic review to identify performance metrics that have
been used, or proposed, for monitoring or measuring per-
formance at sites in multicentre randomised trials.Methods
We performed a systematic review to identify metrics that
have been used or proposed for monitoring or measuring per-
formance at individual sites in multicentre randomised trials.Fig. 1 Flow diagramCriteria for potentially eligible studies
Studies were potentially eligible for inclusion if they:
 Reported one or more site performance metric,
either used or proposed for use, specifically for
the purpose of measuring individual site
performance
 Were multicentre randomised trials, or concerning
multicentre trials
 Were published in English
 Related to randomised trials involving humans
Studies where the strategy for monitoring site per-
formance was randomly allocated were included. We
anticipated that there might be studies where the
adoption of an individual performance metric might
have been tested by randomly allocating sites to using
that particular metric or not. Studies relevant to both
publically funded and industry-funded trials were
included.
Table 1 Characteristics of included studies
Study Study description Number of sites
(sample size)
Metrics reported by each study
Included as site performance
metric
Excluded as not site performance metrica
Studies proposing performance metrics
Bose 2012 [14] Paper discussing trial management
through central monitoring
Not applicable • Site location potential index
based on an assessment of
the number of patients at an
individual site with the disease
of interest
• Trial compliance index based
on a number of suggested factors
including the number of late visits,
failure to achieve recruitment target,
number of dosing errors, etc.
• Drug adversity measurement (B)
• Drug potential index (B)
Djali 2010 [15] Paper discussing a data-driven
quality management system
Not applicable • Enrolment number per siteb
• Recruitment period per site
• Number of AEs per site
• Number of protocol deviations
and violations per site
• Number of discontinuations per
site (A)
• Deaths per site (D)
Elsa 2011 [16] Methodology of developing ‘key risk
indicators’ for monitoring of a large
international clinical trial
Not applicable • Rate of SAE reporting per site:
centres assigned a dichotomous
score depending on whether
they showed extreme deviation
from comparable sites (arbitrarily
defined as half the observed
median rate across sites)
• Short visit duration: centres assigned
a dichotomous score depending on
whether they showed extreme
deviation from comparable sites
(arbitrarily defined as half the observed
median rate across sites)
• Measures of compliance with
study treatment (A)
• Blood results/other continuous
variables examined for unusual
patterns (A)
Glass 2007 [17] Study analysing data retrospectively
from 262 clinical trials to determine
variables associated with successful
trial delivery
Not applicable • Actual number participants randomised
per site
• Number successfully completing the
study’s protocol per site
• Time between when an individual site
randomises its first participant and the
time the first site in that study enrols its
first patient
Hanna, 2013 [11] Development of a list of quality
indicators for trial performance
based on the consensus of experts
Not applicable • SAE reporting measured by the number
of SAEs reported/number of SAEs identified
in trial database or trial follow-up documents
• Transfer of CRF to CTU measured by the
number of completed CRF received by CTU
within 30 days/number of completed CRF
received by the CTU in 3 months
Jou, 2013 [18] Aim of the main study: treatment-naïve,
hepatitis C patients randomised to two
peginterferon regimens. Primary
outcome virologic response. A
retrospective analysis was performed
of individual site performance using
trial data
118 (3070) • Rates of screen failure defined as the
percentage of participants screened
who failed screening
• Completion and discontinuation of
treatment, defined as the percentage
of participants who completed treatment/
percentage of participants who
discontinued treatment
• Completion / discontinuation of
follow-up, defined as the
percentage who completed
follow-up/ percentage who
discontinued follow-up
• Treatment adherence (B)
Khatawkar 2014
[19]
Retrospective analysis of data queries
using clinical trial data
Not applicable • Data query (DQ) rate per page
• DQ rate per page by phase of study
• DQ rate per page by country (B)
• DQ rate per page by therapeutic
area (B)
Lee 2012 [20] Paper describing the output of a
Delphi survey to establish an
‘evaluation framework’ for clinical
trial data
Not applicable • Rapid enrolment, defined as
time taken to reach target
enrolment
• Timely data entry, defined as
time taken for data entry after
completion of informed consent
• Timely manual query management,
defined as time taken for response
to manual query request from data centre
• Timely database lock, defined as
• Weeks after go-live, i.e. after the
point of protocol amendment (A)
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Table 1 Characteristics of included studies (Continued)
Study Study description Number of sites
(sample size)
Metrics reported by each study
Included as site performance
metric
Excluded as not site performance metrica
time taken for database lock
after the last visit of last
participant per site
• Data discrepancy management
metric encompassing number of
manual queries per CRF for
missing data; number of manual
queries per CRF for out -of-range
data; number of manual queries
per CRF for logical consistency
• Protocol compliance metric
encompassing: rate of ‘dropout’
of total participants; rate of false
‘dropout’ of total dropouts; rate
of late detection of ‘dropout’
• Enrolment success defined as %
eligible per study
Rojavin, 2005
[21]
Paper describing and discussing one
proposed metric
Not applicable • Recruitment Index (RI) = (LPFV −
FPFV) x S/P where
LPFV = date of the last participant
first visit
FPFV = date of the first participant
first visit
S = number of participating sites
P = number of participants who
successfully completed the study
Rosendorf, 1993
[22]
Trials of treatment for HIV. No further
details. An evaluation tool was proposed
to monitor individual site performance
within a multicentre randomised trial.
59 (ns) Intensity adjusted score (IAS) =
IAS = IS0 + don x IS1 + doff x IS2
where: IS0 = score assigned for
enrolling a new participant during
the 6 month evaluation period
don = number of days the
participant was on the study
medication during the evaluation
period
doff = number of days the
participant was off the study
medication
IS1 = intensity score for the days
in which the participant is
receiving study medication
IS2 = intensity score for the days
in which the participant is off all
study medication
ISA is calculated for each
participant and then summing scores
across all participants, once during
the evaluation period
• Funding adjusted score = IAS divided
by the amount awarded for total
direct costs during the given time period
• Summary quartiles = total number of
new and continuing participants on study
Sweetman, 2011
[23]
Retrospective analysis of publications of
80 clinical trials on protocol violations
reporting
Not applicable Occurrence of protocol violations, defined as
total number of protocol violations divided by
the number of enrolled participants
Thom, 2011
[12]a
Report of a centre performance
assessment tool used within a clinical
trial network to assess individual site
performance
Not applicable • Protocol adherence, defined as average rate
of protocol violations per enrolled participant
• Data quality, defined as average rate of edit
checks per participant
• Data timeliness, defined as the percentage
of forms entered late
• Time of starting after the first centre start
date
• Sum of protocol adherence, data quality,
data timeliness and timeliness of study
start-up to give overall rank
• Timeliness of study start-up
• Recruitment, defined as average
percentage of participants
contributed over all studies
conducted (B)
• Retention, defined as average
percentage of participants with
complete follow-up data (B)
• Recruitment/retention, defined
as sum of recruitment +
retention to give overall rank (B)
• Adherence/quality (A)
• Quality of laboratory samples
collected (A)
Tudur Smith,
2014 [24]
Paper describing monitoring methods
using a ‘risk proportionate approach’
used by an individual clinical trials unit
Not applicable • Consent form completion, defined as
consent forms returned within 7 days
of completion by sites.
• Case report form completion,
defined as timely submission (A)
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Table 1 Characteristics of included studies (Continued)
Study Study description Number of sites
(sample size)
Metrics reported by each study
Included as site performance
metric
Excluded as not site performance metrica
• Recruitment process, defined as frequency
of eligible participants who do not provide
consent.
• Missing primary outcome data, defined as
cumulative percentage of participants with
missing primary outcome data at each site
• SAEs, defined as cumulative percentage of
participants with at least one SAE across the
trial as a whole and at each site /measure of
time, e.g. 1 month
• Sum of all SAEs/sum of all follow-up for
the trial
• Sum of all follow-up at site x overall SAE
rate for the trial
• Visit dates, defined as time between actual
date of visit versus expected date of visit
Wilson, 2014
[25]
Theoretical paper describing methods
of monitoring the conduct of trials
Not applicable • Quality metric encompassing: average
number of major audit findings per
audited site; percentage per site of
unreported, confirmed SAEs; number of
significant protocol deviations per site
• Frequency of protocol violations for
eligibility criteria and randomisation
per site
• Rates of withdrawal by site
• Proportion of the enrolled
population comprising the non-
randomised parallel cohorts
(measured by percentage
agreement and kappa statistic) (C)
• Radiologic inter-observer
agreement (C)
Studies using performance metrics
Berthon-Jones
2015 [2]
Aim of main study: treatment-naïve
HIV patients randomised to 2
different types of ART. Primary
outcome plasma HIV-RNA, change
from baseline to week 48. Performance
across 5 geographical regions was
assessed using performance metrics
36 (322) • Time from protocol release to ethics/
regulatory submission
• Time from protocol release to ethics/
regulatory approval
• Time from protocol release to first
participant randomised (FPR)
• Time from protocol release to last
participant randomised (LPR)
• Time from site opened to first participant
randomised (FPR)
• Time from first participant randomised (FPR)
to last participant randomised (LPR)
• Actual versus estimated recruitment
• Time from participant visit to electronic data
capture (EDC) initiation
• Time from EDC initiation to completion
• Number of missing values per participant
• Number of data queries per participant
• Number of SAEs reported per participant
• Time from SAE occurrence to initial report
• Time from initial SAE report to final report
• Number of samples collected versus number
required by protocol
• Number of missed visits per
region (B)
• Quality of laboratory sample/s
collected (A)
• Number of plasma samples
collected versus protocol-
mandated samples to be
collected (C)
• Number of buffy-coat samples
collected versus protocol-
mandated samples to be
collected (C)
Katz, 2015 [26] Aim of main studies: osteoarthritis
(2 trials), lower back pain (1 trial)
randomised to fulranumab infusion
or placebo. Primary outcomes unspecified.
Within these three clinical trials a method
of monitoring individual site performance
was applied
40–88 (91–157) • Time to data query response • Compliance with study drug (D)
Kim, 2011 [27]a Aim of main study: patients with acute
cerebral haemorrhage randomised to
early intensive antihypertensive or
standard regimen. Primary outcome
death or disability at 3 months. A site
performance monitoring tool was
incorporated for monitoring individual
site performance during the trial
100 (1280) • Participant recruitment per site
• CRF data collection timeliness +
completeness
• Protocol violations per site
• SAE reporting per site
• Participant study progress (A)
• Site data monitoring visit findings (A)
• Data clarification request processing
(A)
• Regulatory document collection and
tracking (A)
Rifkind, 1983
[28]
Aim of the main study: men with primary
type 2 hyper-lipoproteinaemia randomised
to bile acid sequestrant or placebo. Primary
outcome CHD death and/or nonfatal
myocardial infarction. Within this study
measures of individual site recruitment
performance were monitored.
12 (3550) • Proportion of initial contacts
proceeding to first protocol
visit by recruitment source
• Proportion of first protocol
visits proceeding to study
entry by recruitment source
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Table 1 Characteristics of included studies (Continued)
Study Study description Number of sites
(sample size)
Metrics reported by each study
Included as site performance
metric
Excluded as not site performance metrica
Saunders, 2015
[29]a
Aim of the main study: critical care
patients randomised to probiotic or
placebo. Primary outcome ventilator
associated pneumonia. Within this
study the team focused on screening
performance in individual centres
14 (285) • Non-screening weeks = proportion
of weeks during which participants
were not screened for trial eligibility
•
Sun, 2008 [30] Aim of the main study: patients with
major depression randomised to
aprepitant or placebo. Primary
outcome change in Hamilton
Depression Scale. Within this
study measures of individual site
performance were captured
Not reported • Administration excellence, defined
as site administration performance
and interaction with central study
team rated 1, 2 or 3
• Data quality, defined as data
completeness and correctness at
initial submission rated 1, 2, or 3
• Proportion of participants with
protocol violation, defined as:
proportion of participants in
each site who do not meet
eligibility criteria; have medication
compliance < 75%, or take prohibited
concomitant medication or wrong
study medication; or other serious
violation
• Level of visit non-compliance,
defined as mean absolute
difference of the days between
visits and the protocol-specified
days between visits for participants
in a specific centre
• Level of medication non-compliance, defined as the mean
number of doses of study-assigned medication (B)
Wear, 2010 [31]a Aim of the main study: patients
with multiple myeloma, multiple
clinical trials. No further details.
Performance metrics utilised
during the study
Not reported • First patient dosed (FPD), defined
as time from receipt of final protocol
to the first participant treated
• Enrolment commitment (EC), defined
as commitment from the study site to
provide a predicted number of
participants who will receive at least
1 dose of study drug (e.g. number
of participants randomised and
completing first part of intervention
• Baseline enrolment timeline (BET),
defined as target time period to obtain EC
AE adverse event; ART antiretroviral therapy; CHD coronary heart disease; CRF case record form; CTU clinical trial unit; ns not specified; SAE serious adverse event;
VTE venous thromboembolism
aExcluded due to (a) lack of clarity, (b) not related to individual site performance, (c) too specific to an individual trial methodology, (d) pertaining to clinical
outcomes not trial performance
bIt is unclear from the paper whether enrolment refers to participants randomised to a study or simply consented and then screened for study eligibility
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We searched the Cochrane Library and five biomedical bib-
liographic databases (CINAHL, Excerpta Medica database
(EMBASE), Medical Literature Analysis and Retrieval Sys-
tem Online (Medline), Psychological Information Database
(PsychINFO) and SCOPUS) and Google Scholar from 1980
to 2017 week 07. The search strategy is provided as an
Appendix (Table 3).
Selection of studies
Two reviewers (KW, JT) independently assessed for inclu-
sion the titles and abstracts identified by the search strat-
egy. If there was disagreement about whether a record
should be included, we obtained the full text.
We sought full-text copies for all potentially eligible
records, and two reviewers (KW, JT) independently
assessed these for inclusion. Disagreements were resolvedby discussion, and if agreement could not be reached the
study was independently assessed by a third reviewer (LD).
Multiple reports of the same study were linked together.
Data extraction and data entry
Two reviewers (KW, JT) extracted data independently
onto a specifically designed data extraction form. In the
few cases where full text was not available (n = 9), data
were extracted using the title and abstract only. Data
were entered into an Excel spreadsheet, and checked.
Data were extracted on the design of the randomised trial
(participants, intervention, control, number of sites and tar-
get sample size); whether the performance metric/s was
theoretical or applied. For each performance metric we col-
lected data that included: a verbatim description of the
metric; how the metric was measured or expressed; timing
of the measurement and during which phase of the study;
Table 2 Examples of performance metrics within each identified
category
Categories Example performance
metric
Studies in which
metric included
Assessing site potential Site location potential index
based on an assessment of
the number of patients at
an individual site with the
disease of interest
[14]
Monitoring
recruitment
Number of participants
randomised per site
[15, 17, 27]
Monitoring retention Rates of withdrawal by site [20, 25]
Quality of data
collection
Number of data queries
per participant
[2, 12, 19]
Trial conduct Protocol violations per site
or per participant
[12, 15, 23, 27, 30]
Trial safety Serious adverse event
(SAE) reporting
per site
[11, 24, 27]
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tion, what the threshold was and what action it triggers;
and whether the metric was recommended by the authors.
Data analysis
We described the flow of studies through the review, with
reasons for being removed or excluded, using the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidance [10]. Characteristics of each study were
described and tabulated. Analyses were descriptive only,
with no statistical analyses anticipated.
Results
The database search identified 3365 records, of which 177
were duplicates, leaving 3188 screened for eligibility (Fig. 1).
At screening, we obtained full-text copies for 147 records to
determine eligibility. For a further seven records full-text cop-
ies were unavailable, and so screened was based on the ab-
stract only. Of those full-text copies and abstracts (for papers
where the full text was unavailable), there was disagreement
on three papers. Following discussion two papers were ac-
cepted for inclusion [11, 12] and one paper was excluded [13].
Twenty-one studies were agreed for inclusion, of which
14 were studies proposing performance metrics and seven
were studies using performance metrics (Table 1). These 21
studies reported a total of 117 performance metrics. The
median number of performance metrics reported per study
was 8, with the range being 1–16. Those 117 metrics were
then screened, to exclude any judged as: lacking sufficient
clarity; being unrelated to individual site performance; being
too specific to an individual trial methodology or pertaining
to clinical outcomes not trial performance. This left 87 per-
formance metrics to be considered for use in day-to-day trial
management. The metrics broadly fell into six main categor-
ies: assessing site potential before recruitment starts; andmonitoring recruitment, retention, quality of data collection,
quality of trial conduct, and trial safety (Table 2).
Discussion
As far as we are aware, this is the first systematic review to
identify and describe proposed or utilised metrics to monitor
site performance in multicentre randomised trials. It provides a
list of performance metrics, which can be used to contribute to
developing and agreed a proposed set of performance metrics
for use in day-to-day trial management. We identified 87 per-
formance metrics which fell broadly into six main categories.
A strength of our study was the comprehensive search
of the literature.
In planning this systematic review we envisaged that studies
would be identified that had evaluated individual performance
metrics either by implementation mid-way through a study,
or ideally by randomising individual sites to use of a particular
metric or not. Unfortunately, there was a paucity of such
studies. Most studies suggested performance metrics on a
purely theoretical basis, and did not provide data on the ac-
tual use of suggested metrics. The main limitations of our
study were the lack of studies implementing performance
metrics and reporting the effects of their utilisation, and that
published work on this topic is limited, which is perhaps sur-
prising as informal assessment of how sites perform in multi-
centre trials is common.
This list of performance metrics contributed to develop-
ment of a Delphi survey sent to trial managers, UKCRC CTU
directors and key clinical trial stakeholders, which is reported
elsewhere. They were invited to participate through the UK
Trial Managers’ Network (UK TMN) and UK Clinical Re-
search Collaboration (UKCRC CTU) Network. Three Delphi
rounds were used to steer the groups to consensus, refining
the list of performance metrics. The reasons for their deci-
sions were documented. Finally, data from the Delphi survey
was presented to stakeholders in a priority setting expert
workshop, providing participants with the opportunity to ex-
press their views, hear different perspectives and think more
widely about monitoring of site performance. This was used
to establish a consensus among experts on the top key per-
formance metrics, expected to number around 8–12.
Conclusions
This study provides trialists for the first time with a compre-
hensive description of performance metrics described in the
literature that have been proposed or used in the context of
multicentre randomised trials. It will assist future work to de-
velop a concise, practical list of performance metrics which
could be used in day-to-day trial management to improve
the performance of individual sites. This has the potential to
reduce both the financial cost of delivering a multicentre
trial, and the research waste and delay in scientific progress
that results when trials fail to meet their recruitment target,
are poorly conducted, or have inadequate data.
Appendix
Table 3 Search strategy. Monitoring performance of sites within
multicentre randomised trials: a systematic review of performance
metrics
# Searches
1 Randomised. controlled trial
2 Clinical trial
3 Pragmatic trial
4 Controlled clinical trial
5 1 or 2 or 3 or 4
6 Performance indicator
7 Performance metric
8 Performance measure
9 Enrollment rate
10 Participant enrollment
11 Participant recruitment
12 Quality indicator
13 Quality measure
14 Performance management
15 Assessing site performance
16 Central monitoring
17 Clinical trial monitoring
18 Clinical trial reporting
19 Trial analytics
20 Trial management
21 Site performance
22 Study conduct
23 Trial site performance
24 Benchmarking performance
25 Clinical data management
26 Clinical trial data quality
27 Laboratory sample quality in clinical trials
28 Operational metrics
29 Operational performance
30 Performance evaluation
31 Performance monitoring
32 Performance score
33 Protocol deviations
34 Protocol violations
35 Quality management system
36 Recruitment index
37 Screening logs
38 Strategic project management
39 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
or 14 or 15 or 16 or 17 or 18 or 19
or 20 or 21 or 22 or 23 or 24 or 25 or 26
or 27 or 28 or 29 or 30 or 31 or 32
or 33 or 34 or 35 or 36 or 37 or 38
Table 3 Search strategy. Monitoring performance of sites within
multicentre randomised trials: a systematic review of performance
metrics (Continued)
# Searches
40 39 and 5
41 40 Not (animals/ not humans.sh.)
42 40
Walker et al. Trials  (2018) 19:562 Page 8 of 9Abbreviations
CINAHL: Cumulative Index to Nursing and Allied Healthy Literature; CRF: Case
report form; CTUs: Clinical Trials Units; EMBASE: Excerpta Medica database;
Medline: Medical Literature Analysis and Retrieval System Online; NIHR: National
Institute for Health Research; PRISMA: Preferred Reporting Items for Systematic
Reviews and Meta-Analyses; PsychINFO: Psychological Information Database; UK
TMN: UK Trial Managers’ Network; UKCRC: UK Clinical Research Collaboration
Funding
This work was funded by NIHR CTU Support funding. The views expressed
are those of the author(s) and not necessarily those of the National Health
Service (NHS), the National Institute for Health Research (NIHR) or the
Department of Health.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
LD and DW conceived the study. LD, DW, JT, KW and AM designed the
study and wrote the protocol. JT and KW performed the search and
collected the data. KW analysed the data and drafted the paper with input
from LD and JT. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Received: 15 May 2018 Accepted: 26 September 2018
References
1. Duley L, Antman K, Arena J, Avezum A, Blumenthal M, Bosch J, Chrolavicius
S, Li T, Ounpuu S, Perez AC, et al. Specific barriers to the conduct of
randomized trials. Clin Trials. 2008;5(1):40–8.
2. Berthon-Jones N, Courtney-Vega K, Donaldson A, Haskelberg H, Emery S,
Puls R. Assessing site performance in the Altair study, a multinational clinical
trial. Trials. 2015;16(1):138 (no pagination).
3. Coleby D, Whitham D, Duley L. Can site performance be predicted? Results
of an evaluation of the performance of a site selection questionnaire in five
multicentre trials. Trials. 2015;16(Suppl 2):176.
4. Kirkwood AA, Cox T, Hackshaw A. Application of methods for central
statistical monitoring in clinical trials. Clin Trials. 2013;10(5):783–806.
5. Bakobaki JM, Rauchenberger M, Joffe N, et al. The potential for central
monitoring techniques to replace on-site monitoring: Findings from an
international multi-centre clinical trial. Clin Trials 2012;9:257–64.
43 Limit 42 to English language
Walker et al. Trials  (2018) 19:562 Page 9 of 96. Timmermans C, Venet D, Burzykowski T. Data-driven risk identification in
phase III clinical trials using central statistical monitoring. Int J Clin Oncol.
2016;21(1):38–45.
7. Tantsyura V, Dunn IM, Fendt K, Kim YJ, Waters J, Mitchel J. Risk-based
monitoring: a closer statistical look at source document verification, queries,
study size effects, and data quality. Ther Innov Regul Sci. 2015;49(6):903–10.
8. Smith B, Martin L, Martin S, Denslow M, Hutchens M, Hawkins C, Panier V,
Ringel MS. What drives site performance in clinical trials? Nat Rev Drug
Discov. 2018;17(6):389–90.
9. Dorricott K. Using metrics to direct performance improvement efforts in
clinical trial management. Monitor. 2012;26(4):9–13.
10. Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P. Preferred Reporting Items
for Systematic Reviews and Meta-Analyses: the PRISMA Statement. J Clin
Epidemiol. 2009;62(10):1006–12.
11. Hanna M, Minga A, Fao P, Borand L, Diouf A, Mben JM, Gad RR, Anglaret X,
Bazin B, Chene G. Development of a checklist of quality indicators for clinical
trials in resource-limited countries: The French National Agency for Research
on AIDS and Viral Hepatitis (ANRS) experience. Clin Trials. 2013;10(2):300–18.
12. Thom E. A center performance assessment tool in a multicenter clinical
trials network. Clin Trials. 2011;8(4):519.
13. Hullsiek KH, Wyman N, Kagan J, Grarup J, Carey C, Hudson F, Finley E,
Belloso W. Design of an international cluster-randomized trial comparing
two data monitoring practices. Clin Trials. 2013;10:S32–3.
14. Bose A, Das S. Trial analytics—A tool for clinical trial management. Acta
Poloniae Pharmaceutica - Drug Research. 2012;69(3):523–33.
15. Djali S, Janssens S, Van Yper S, Van Parijs J. How a data-driven quality
management system can manage compliance risk in clinical trials. Drug
Inform J. 2010;44(4):359–73.
16. Elsa VM, Jemma HC, Martin L, Jane A. A key risk indicator approach to central
statistical monitoring in multicentre clinical trials: method development in the
context of an ongoing large-scale randomized trial. Trials Conference: Clinical
Trials Methodology Conference. 2011;12:1.
17. Glass HE, DiFrancesco JJ. Understanding site performance differences in
multinational phase III clinical trials. Int J Pharmaceutical Med. 2007;21(4):279–86.
18. Jou JH, Sulkowski MS, Noviello S, Long J, Pedicone LD, McHutchison JG,
Muir AJ. Analysis of site performance in academic-based and community-
based centers in the IDEAL study. J Clin Gastroenterol. 2013;47(10):e91–5.
19. Khatawkar S, Bhatt A, Shetty R, Dsilva P. Analysis of data query as parameter
of quality. Perspect Clin Res. 2014;5(3):121–4.
20. Lee HJ, Lee S. An exploratory evaluation framework for e-clinical data
management performance. Drug Inf J. 2012;46(5):555–64.
21. Rojavin MA. Recruitment index as a measure of patient recruitment activity
in clinical trials. Contemp Clin Trials. 2005;26(5):552–6.
22. Rosendorf LL, Dafni U, Amato DA, Lunghofer B, Bartlett JG, Leedom JM,
Wara DW, Armstrong JA, Godfrey E, Sukkestad E, et al. Performance
evaluation in multicenter clinical trials: Development of a model by the
AIDS Clinical Trials Group. Control Clin Trials. 1993;14(6):523–37.
23. Sweetman EA, Doig GS. Failure to report protocol violations in clinical trials:
a threat to internal validity? Trials. 2011;12:214 (no pagination).
24. Tudur Smith C, Williamson P, Jones A, Smyth A, Hewer SL, Gamble C. Risk-
proportionate clinical trial monitoring: an example approach from a non-
commercial trials unit. Trials. 2014;15(1):127 (no pagination).
25. Wilson B, Provencher T, Gough J, Clark S, Abdrachitov R, de Roeck K,
Constantine SJ, Knepper D, Lawton A. Defining a central monitoring
capability: sharing the experience of TransCelerate BioPharma's approach,
Part 1. Ther Innov Regul Sci. 2014;48(5):529–35.
26. Katz N. Development and validation of a clinical trial data surveillance
method to improve assay sensitivity in clinical trials. J Pain. 2015;1:S88.
27. Kim J, Zhao W, Pauls K, Goddard T. Integration of site performance monitoring
module in web-based CTMS for a global trial. Clin Trials. 2011;8(4):450.
28. Rifkind BM. Participant recruitment to the coronary primary prevention trial.
J Chronic Dis. 1983;36(6):451–65.
29. Saunders L, Clarke F, Hand L, Jakab M, Watpool I, Good J, Heels-Ansdell D.
Screening weeks: a pilot trial management metric. Crit Care Med. 2015;1:330.
30. Sun J, Wang J, Liu G. Evaluation of the quality of investigative centers using
clinical ratings and compliance data. Contemp Clin Trials. 2008;29(2):252–8.
31. Wear S, Richardson PG, Revta C, Vij R, Fiala M, Lonial S, Francis D, DiCapua
Siegel DS, Schramm A, Jakubowiak AJ, et al. The multiple myeloma research
consortium (MMRC) model: Reduced time to trial activation and improved
accrual metrics. Blood Conference: 52nd Annual Meeting of the American
Society of Hematology, ASH. 2010;116(21):3803.
